Fulcrum Therapeutics Inc. has unveiled its corporate presentation for August 2025, highlighting strategic developments in their pipeline for genetically defined rare diseases. The company focuses on developing oral small molecules to modify gene expression, particularly in benign hematology. A key asset, Pociredir, is positioned as a potential best-in-class oral small molecule for inducing fetal hemoglobin (HbF) in Sickle Cell Disease $(SCD)$. Pociredir has shown significant increases in HbF and hemoglobin (Hb), alongside decreases in vaso-occlusive crises (VOCs), hemolysis, and anemia. It holds Fast Track and Orphan Drug Designations and is protected by patents through 2040. Fulcrum is advancing its discovery programs with an investigational new drug (IND) submission for Diamond Blackfan Anemia $(DBA)$ and other Bone Marrow Failure Syndromes (BMFS) planned for Q4 2025. The company reported a cash position of $214.1 million as of June 30, 2025, with a financial runway into 2028. You can access the full presentation through the link below.